UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 Current Report


     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of report (date of earliest event reported): April 30, 2007

                               Balchem Corporation
             (Exact name of registrant as specified in its charter)

Maryland                                   1-13648           13-257-8432
(State or other jurisdiction of   (Commission File Number)   (IRS Employer
incorporation)                                               Identification No.)

                       P.O. Box 600, New Hampton, NY 10958
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (845) 326-5600

         Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[_]     Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

[_]     Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)

[_]     Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

[_]     Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

<page>


Item 8.01 Other Events

         On  April  30,  2007,  Balchem  Corporation  ("Balchem"),  through  its
European subsidiary Balchem B.V.,  completed its acquisition of the methylamines
and  choline  chloride  business  and  manufacturing  facilities  of Akzo  Nobel
Chemicals  S.p.A.  ("Akzo"),  located in Marano Ticino,  Italy for a provisional
purchase price of  (euro)4,599,000.  Such amount is subject to adjustment  after
the closing based upon actual  finished goods and raw materials  inventory as of
the closing date, as well as reconciliation of the other estimated  constituents
of the provisional purchase price (the  "Acquisition").  The parties believe the
final  purchase price will be fully settled no later than 90 days after closing.
The  terms  and  conditions  of the  Acquisition  are set  forth in the Sale and
Purchase  Agreement,  dated March 30, 2007, between Balchem B.V. and Akzo and is
incorporated  herein by reference to Exhibit 10.1 to the Current  Report on Form
8-K of the  Company,  dated  April  4,  2007  (the  "Purchase  Agreement").  The
Acquisition was previously announced on April 2, 2007. Balchem B.V. assigned the
Purchase  Agreement in its  entirety to Balchem  Italia  S.r.l.,  a wholly owned
subsidiary of Balchem B.V.

         On May 1, 2007,  the  Company  issued a press  release  announcing  the
closing of the  Acquisition.  A copy of the press release is attached  hereto as
Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d)  Exhibits

         Exhibit 99.1    Press Release of Balchem Corporation dated May 1, 2007.


<page>


                                    SIGNATURE

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                     BALCHEM CORPORATION


                                                     By: /s/ Dino A. Rossi
                                                     --------------------------
                                                     Dino A. Rossi, President &
                                                     Chief Executive Officer

Dated: May 4, 2007


<page>


                                  Exhibit Index


(d)  Exhibits

         Exhibit 99.1    Press Release of Balchem Corporation dated May 1, 2007.